17th Expert Committee on the Selection and Use of Essential Medicines: Medicines for children

Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines

The 2nd List of Essential Medicines for Children will be reviewed by the 17th Expert Committee in March 2009.

Comments on the 2nd EMLC

• Comments from Cécile MACE, International Union Against Tuberculosis and Lung Disease
  pdf, 13kb
• Comments from Dr D. Fuller on fluoroquinolones in children
  pdf, 195kb
• Comments from PATH: Application to the WHO model list of essential medicines for Chlorhexidine Digluconate 4% for Umbilical Cord Care
  pdf, 30kb
• Comments from USAID: Chlorhexidine Digluconate 4% for Umbilical Cord Care
  pdf, 566kb
• Request for denial of ciprofloxacin as part of section 6.2.2 Other antibiotics
  pdf, 15kb

Applications for paediatric medicines

• Access to Essential Diabetes Medicines for Children in the Developing World
• Antiemetic medicines (Inclusion) -- Paediatrics [NEW]
• Antituberculosis medicines (Inclusion) -- Paediatrics [NEW]
• Artemether + lumefantrine (Inclusion) -- Paediatrics
• Captopril (Inclusion) -- Paediatrics
• Carvedilol (Inclusion) -- Paediatrics
• Ibuprofen (Inclusion) -- Paediatrics
• Liposomal amphotericin B (Inclusion) -- Paediatrics [NEW]
• Procaine benzylpenicillin (Review) -- (Paediatrics) [NEW]

Comments on the Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children

• Comments from PFI Members
  pdf, 51kb
• Other comments from PFI Members
  pdf, 31kb
• Comments from Abbott
  pdf, 61kb
• Comments from Theo Dekker
  pdf, 12kb
• Comments of the Malta Chamber of Pharmacists
  pdf, 114kb
• Comments from Councillors of the Commonwealth Pharmacists Association
  pdf, 25kb
• Comments from FIP Project Manager
  pdf, 94kb